Abstract
Prostatitis is a common condition which can affect men of all ages; however, it is more frequently experienced in younger men with an initial onset around 40 years of age. The two main presenting clinical features of prostatitis are lower urinary tract symptoms and pelvic pain. Other symptoms might include obstructive or irritative voiding symptoms, ejaculatory pain, and hematospermia. A diagnosis is usually based on the man's history, physical examination, urinalysis, and the two-or four-glass test (also known as obtaining urine specimens before, during, and after prostatic massage). Further investigations may also be performed when considering the differential diagnosis. Prostatitis can result in a significant reduction in quality of life (QOL) and pain can be associated with sexual dysfunction in men. Prostatitis can be classified as four distinct types, namely, type I acute prostatitis, type II chronic bacterial prostatitis, type III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and type IV asymptomatic prostatitis. It is unclear whether type III can be linked in all cases to prostatic involvement therefore the alternate denomination CPPS is used in clinical practice. Furthermore, CP/CPPS is further subclassified as type IIIa (inflammatory), and type IIIb (noninflammatory) which is dependent on the presence of inflammatory cells in prostatic secretions. CP/CPPS is considered when pelvic pain is present for at least three of the preceding 6 months with no other identifiable causes determined. There are several hypothesized causes of CP/CPPS which include: neuropsychological factors, infection, inflammation/autoimmunity, and dyssynergia voiding associated with bladder neck hypertrophy. Given the wide range of potential causes of CP/CPPS, there are many pharmacological interventions available in clinical practice to manage this complex condition. It is important to critically summarize evidence-based recommendations to inform the clinical management of men affected by CP/CPPS (Franco et al., 2019).
Highlights
The Mission of Cochrane Nursing (CN) is to support Cochrane’s work by increasing the use of their library and provide an international evidence base for nurses and related healthcare professionals involved in delivering, leading or researching nursing care
The reviewers were uncertain about the effects of Alpha blockers on prostatitis symptoms when compared to placebo at both short- and long-term follow-up
The findings suggest that Alpha blockers probably result in little to no difference in sexual dysfunction, quality of life and anxiety and depression
Summary
The Mission of Cochrane Nursing (CN) is to support Cochrane’s work by increasing the use of their library and provide an international evidence base for nurses and related healthcare professionals involved in delivering, leading or researching nursing care. TITLE: Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome Prostatitis can result in a significant reduction in quality of life (QOL) and pain can be associated with sexual dysfunction in men.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
